Company / Current Liabilities
GT Biopharma, Inc. Current Liabilities History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$35.1M
FY2020
5-year range
$2.7M / $61.2M
FY2016-FY2020
Trend
+1210.0%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities changed +1210% YoY in FY2020, a notable deviation from the 7-year average annual change of +230%.
Based on SEC 10-K filings.
$35M in FY2020 with a 5-year CAGR of +3.3%.
Improved from $61M to $35M over the past 4 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +135.7%
- 5-Year CAGR
- +3.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +3.3%, indicating consistent growth.
- In FY2020, current liabilities increased 1210.0% year-over-year.
- Peak current liabilities was recorded in FY2016.
- Lowest current liabilities in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $35.1M | +1210.0% |
| FY2017 | $2.7M | -95.6% |
| FY2016 | $61.2M | +105.1% |
| FY2015 | $29.8M | +0.0% |
| FY2014 | $29.8M | +367.2% |
| FY2013 | $6.4M | -2.7% |
| FY2012 | $6.6M | +25.5% |
| FY2011 | $5.2M | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026